Dolasynthen, Publications, XMT-1660 XMT-1660: A Phase 1b Trial of a B7-H4–targeting Antibody-Drug Conjugate (ADC) in Endometrial, Ovarian, and Breast Cancers
Dolasynthen, Publications, XMT-1660 Anti-tumor effect of XMT-1660, a B7-H4 targeting antibody drug conjugate, in an unselected panel of patient derived xenograft models of breast cancer April, 2022
Dolasynthen, Platform, Publications, XMT-1660 XMT-1660, a B7-H4-Targeted Dolasynthen Antibody-Drug Conjugate for the Treatment of Breast Cancer April, 2021
